Cowen & Co. Maintains a Buy Rating on Avrobio Inc (AVRO)

By Ryan Adsit

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Avrobio Inc (AVROResearch Report). The company’s shares closed yesterday at $18.53, close to its 52-week low of $11.85.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 51.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Avrobio Inc is a Moderate Buy with an average price target of $40, implying an 115.9% upside from current levels. In a report issued on April 22, H.C. Wainwright also maintained a Buy rating on the stock with a $40 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $53.70 and a one-year low of $11.85. Currently, Avrobio Inc has an average volume of 180.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. The company was founded by Jeffrey Medin and Christopher Paige in 2015 and is headquartered in Cambridge, MA.